Stoke Therapeutics, Inc. (NASDAQ:STOK) General Counsel Jonathan Allan Sells 2,266 Shares

Stoke Therapeutics, Inc. (NASDAQ:STOK) General Counsel Jonathan Allan sold 2,266 shares of the firm’s stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $19,646.22. Following the transaction, the general counsel now directly owns 33,510 shares of the company’s stock, valued at $290,531.70. This represents a 6.33 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Stoke Therapeutics Stock Performance

STOK stock opened at $8.33 on Friday. The firm has a 50 day simple moving average of $9.49 and a 200 day simple moving average of $11.49. Stoke Therapeutics, Inc. has a 52 week low of $5.80 and a 52 week high of $17.58. The stock has a market cap of $441.22 million, a P/E ratio of -3.97 and a beta of 0.99.

Stoke Therapeutics (NASDAQ:STOK) last issued its earnings results on Monday, March 24th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.38. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The company had revenue of $22.61 million during the quarter, compared to analyst estimates of $4.20 million. Sell-side analysts predict that Stoke Therapeutics, Inc. will post -2.01 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on STOK shares. Chardan Capital restated a “buy” rating and set a $24.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday. Cantor Fitzgerald restated an “overweight” rating on shares of Stoke Therapeutics in a report on Tuesday, December 10th. Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 price target on shares of Stoke Therapeutics in a report on Tuesday. Finally, HC Wainwright reissued a “buy” rating and set a $47.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $23.00.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of STOK. KLP Kapitalforvaltning AS acquired a new stake in shares of Stoke Therapeutics during the 4th quarter valued at about $63,000. Teacher Retirement System of Texas bought a new stake in Stoke Therapeutics in the fourth quarter worth approximately $113,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Stoke Therapeutics during the 4th quarter valued at $124,000. Tower Research Capital LLC TRC raised its holdings in shares of Stoke Therapeutics by 70.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 11,930 shares of the company’s stock valued at $132,000 after purchasing an additional 4,918 shares in the last quarter. Finally, Invesco Ltd. bought a new stake in Stoke Therapeutics in the fourth quarter worth $133,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.